News
Public · Published
Caris Life Sciences 3Q 2026: Revenue $275.36M, Net income $15.25M, EPS $0.05— 10-Q Summary
Caris Life Sciences reported third-quarter 2026 revenue of $275.36 million, up 27% year over year, while net income was $15.25 million and diluted earnings per share was $0.05. Clinical cases rose 21% to 61,500, with testing volume and reimbursement contributing to profiling revenue.
Published:
Updated:
What happened
Caris Life Sciences reported third-quarter 2026 revenue of $275.36 million, up 27% year over year, while net income was $15.25 million and diluted earnings per share was $0.05. Clinical cases rose 21% to 61,500, with testing volume and reimbursement contributing to profiling revenue.
Confirmed
Global impact / market context
Revenue growth alongside lower net income shows that higher testing activity has not translated into higher reported profit so far. Continued spending on laboratories, technology, commercial capacity and research could support future sales, but it may also add costs before those sales arrive.
Analyst inference
The company attributes revenue growth to clinical testing volume, molecular profiling and reimbursement. It also expects adoption and testing volumes to support growth in 2026 and beyond, but those expectations are forward-looking; the reported quarter shows net income and earnings per share declined.
Analyst inference
What to watch
- Track whether clinical cases and profiling revenue continue to grow, since the company links higher testing volume and reimbursement to revenue gains. Analyst inference
- Compare future revenue growth with net income and earnings per share to see whether expanding sales begin to improve profit rather than only increase activity. Analyst inference
- Watch how laboratory, technology, commercial and research spending develops, and whether adoption of Caris Assure and the expanded portfolio supports the company’s stated growth plans. Analyst inference
Evidence
- Original source link unavailable